- Home
- / Tarsus Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Tarsus Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$43.9
2024-10-29
Market Capitalization
$1.7 B
2024-10-29
Revenue
$451.4 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|
| Revenue | 25.8M | 17.4M | 183.0M | 451.4M |
| Cost of goods sold | 955.0K | 1.6M | 12.8M | |
| Gross profit | 24.9M | 15.9M | 170.1M | |
| Gross profit margin, % | 96.3% | 90.9% | 93.0% | |
| General and administrative expense | 44.9M | 108.7M | 237.3M | 427.3M |
| Operating expense total | 87.6M | 159.0M | 290.7M | 491.6M |
| EBIT | (62.7M) | (143.2M) | (120.6M) | (71.0M) |
| EBIT margin, % | -242.9% | -820.5% | -65.9% | -15.7% |
| Interest income | 3.5M | 10.3M | 15.0M | 15.7M |
| Interest expense | 2.2M | 3.3M | 7.8M | |
| Pre tax profit | (62.1M) | (135.9M) | (115.6M) | (64.4M) |
| Income tax expense | (4.0K) | 2.1M | ||
| Net Income | (62.1M) | (135.9M) | (115.6M) | (66.4M) |
| EPS | (2.5) | (4.6) | (3.1) | (1.6) |